{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:59:26Z","timestamp":1791939566650,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.antiviral.2006.08.005","type":"journal-article","created":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T11:32:28Z","timestamp":1158060748000},"page":"118-125","source":"Crossref","is-referenced-by-count":35,"title":["Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses"],"prefix":"10.1016","volume":"73","author":[{"given":"Victor E.","family":"Buckwold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuhui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Nalca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ptak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Scribner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Blanchett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2006.08.005_bib1","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1177\/1352458519950101044","article-title":"Human omega interferon\u2014a review","volume":"1","author":"Adolf","year":"1995","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.antiviral.2006.08.005_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3201\/eid0801.010252","article-title":"Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro","volume":"8","author":"Anderson","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2006.08.005_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/jac\/dkh126","article-title":"Implications of finding synergistic in vitro drug-drug interactions between interferon-\u03b1 and ribavirin for the treatment of hepatitis C virus","volume":"53","author":"Buckwold","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2006.08.005_bib4","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/AAC.47.7.2293-2298.2003","article-title":"Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication","volume":"47","author":"Buckwold","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.08.005_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1742-7843.2006.pto_365.x","article-title":"Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega interferon produced from CHO-SS cells","volume":"99","author":"Buckwold","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.antiviral.2006.08.005_bib6","doi-asserted-by":"crossref","first-page":"11148","DOI":"10.1128\/JVI.76.21.11148-11154.2002","article-title":"Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons","volume":"76","author":"Cheney","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2006.08.005_bib7","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1016\/S0021-9258(17)40698-3","article-title":"Regulation of the erythroid Kruppel-like factor (EKLF) gene promoter by the erythroid transcription factor GATA-1","volume":"269","author":"Crossley","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2006.08.005_bib8","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1073\/pnas.87.10.3743","article-title":"An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes","volume":"87","author":"Driggers","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2006.08.005_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0092-8674(89)90877-5","article-title":"The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain","volume":"59","author":"Frain","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2006.08.005_bib10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/jhep.2000.16661","article-title":"A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C","volume":"32","author":"Glue","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2006.08.005_bib11","first-page":"67651","article-title":"HCV RNA results from a phase II, randomized, open-label study of omega interferon (IFN) with or without ribavirin in IFN-na\u00efve genotype 1 chronic HCV patients","author":"Gorbakov","year":"2005","journal-title":"AASLD Meeting"},{"key":"10.1016\/j.antiviral.2006.08.005_bib12","doi-asserted-by":"crossref","first-page":"9790","DOI":"10.1074\/jbc.M212929200","article-title":"Malignant transformation of melanocytes to melanoma by constitutive activation of MAP kinase kinase signaling","volume":"278","author":"Govindarajan","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2006.08.005_bib13","doi-asserted-by":"crossref","first-page":"21958","DOI":"10.1074\/jbc.270.37.21958","article-title":"Molecular cloning and functional analysis of the promoter of the human squalene synthase gene","volume":"270","author":"Guan","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2006.08.005_bib14","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1128\/MCB.12.11.4919","article-title":"Phylogenetic footprinting reveals a nuclear protein which binds to silencer sequences in the human gamma and epsilon globin genes","volume":"12","author":"Gumucio","year":"1992","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.antiviral.2006.08.005_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4889(03)00080-6","article-title":"Use of an array technology for profiling and comparing transcription factors activated by TNFalpha and PMA in HeLa cells","volume":"1642","author":"Jiang","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.antiviral.2006.08.005_bib16","doi-asserted-by":"crossref","first-page":"38480","DOI":"10.1074\/jbc.M403948200","article-title":"Protein-DNA array-based identification of transcription factor activities regulated by interaction with the glucocorticoid receptor","volume":"279","author":"Jiang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2006.08.005_bib17","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1086\/315847","article-title":"Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells","volume":"182","author":"Jordan","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2006.08.005_bib18","doi-asserted-by":"crossref","first-page":"11813","DOI":"10.1073\/pnas.94.22.11813","article-title":"The crystal structure of human interferon beta at 2.2-A resolution","volume":"94","author":"Karpusas","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2006.08.005_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.47.1.124-129.2003","article-title":"Ribavirin quantification in combination treatment of chronic hepatitis C","volume":"47","author":"Larrat","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.08.005_bib20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","article-title":"Pathogenesis, natural history, treatment, and prevention of hepatitis C","volume":"132","author":"Liang","year":"2000","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.antiviral.2006.08.005_bib21","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1128\/MCB.11.10.5229","article-title":"LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes","volume":"11","author":"Lo","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.antiviral.2006.08.005_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1128\/JCM.37.2.327-332.1999","article-title":"High-throughput real-time reverse transcription-PCR quantitation of heaptitis C virus RNA","volume":"37","author":"Martell","year":"1999","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2006.08.005_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-3542(02)00013-X","article-title":"Identification of active antiviral compounds against a New York isolate of West Nile virus","volume":"55","author":"Morrey","year":"2002","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2006.08.005_bib24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1006\/geno.1998.5288","article-title":"Mouse forkhead (winged helix) gene LUN encodes a transactivator that acts in the lung","volume":"50","author":"Miura","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.antiviral.2006.08.005_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2004.09.002","article-title":"Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy","volume":"65","author":"Okuse","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2006.08.005_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.amjmed.2004.03.024","article-title":"Hepatitis C treatment update","volume":"117","author":"Pearlman","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.antiviral.2006.08.005_bib27","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1128\/JVI.76.8.4008-4021.2002","article-title":"Persistent and transient replication of full-length hepatitis C virus genomes in cell culture","volume":"76","author":"Pietschmann","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2006.08.005_bib28","doi-asserted-by":"crossref","unstructured":"Plauth, M., Jetschmann, J.-U., Meisel, H., Langecker, P.J., Moran, M., Lang, W., Blanchett, D., Brack, J., Von Wussow, P., 2002. Open-label study of omega interferon in previously untreated HCV-infected patients. In: Proceedings of the 37th Annual Meeting EASL (Abstract 208).","DOI":"10.1016\/S0168-8278(02)80444-5"},{"key":"10.1016\/j.antiviral.2006.08.005_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2165\/00003495-200262030-00009","article-title":"Interferon-\u03b1-2b plus ribavirin. A review of its use in the management of chronic hepatitis C","volume":"62","author":"Scott","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2006.08.005_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Ann. Rev. Biochem."},{"key":"10.1016\/j.antiviral.2006.08.005_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000050085","article-title":"Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load","volume":"45","author":"Tsubota","year":"2002","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2006.08.005_bib32","first-page":"52","article-title":"Three-dimensional models of interferon-alpha subtypes IFN-con1, IFN-alpha8, and IFN-alpha1 derived from the crystal structure of IFN-alpha2b","volume":"24","author":"Walter","year":"1997","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.antiviral.2006.08.005_bib33","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1128\/MCB.16.9.4744","article-title":"The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element","volume":"16","author":"Ye","year":"1996","journal-title":"Mol. Cell. Biol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354206002592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354206002592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T20:42:47Z","timestamp":1736541767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354206002592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0166354206002592"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2006.08.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}